Industry
Biotechnology
Precision BioSciences, Inc., a clinical stage gene editing company, develops in vivo gene editing and ex vivo allogeneic CAR T therapies in the United States. It offers ARCUS, a genome editing platform to cure genetic disorders. The company also provides Ex vivo Allogeneic CAR T Immunotherapy, a form of immunotherapy in which T cell, a specific type of immune cell is genetically engineered to recognize and kill cancer cells; PBCAR0191, which is in Phase 1/2a clinical trial in adult patients with R/R NHL or R/R B-cell precursor acute lymphoblastic leukemia, or B-ALL; PBCAR19B, an anti-CD19 CAR T candidate built on the stealth cell platform utilizing a single-step gene edit to minimize the risk of chromosome abnormalities; and PBCAR269A, an investigational allogeneic CAR T immunotherapy targeting BCMA for the treatment of R/R multiple myeloma. The company has development and commercial license agreement with Les Laboratoires Servier to develop allogeneic chimeric antigen receptor T cell therapies for antigen targets, hematological cancer targets beyond CD19, and solid tumor targets; Tiziana Life Sciences to evaluate foralumab, a fully human anti-CD3 monoclonal antibody as a lymphodepleting agent for the potential treatment of cancers; and iECURE, Inc. to develop ARCUS-based gene editing therapies. Precision BioSciences, Inc. was incorporated in 2006 and is headquartered in Durham, North Carolina.
Loading...
Open
6.12
Mkt cap
42M
Volume
94K
High
6.15
P/E Ratio
13.60
52-wk high
19.43
Low
5.38
Div yield
N/A
52-wk low
5.12
Portfolio Pulse from Benzinga Newsdesk
October 24, 2024 | 8:26 pm
Portfolio Pulse from Benzinga Newsdesk
October 24, 2024 | 12:50 pm
Portfolio Pulse from Benzinga Newsdesk
September 30, 2024 | 11:03 am
Portfolio Pulse from Benzinga Newsdesk
September 03, 2024 | 11:27 am
Portfolio Pulse from Benzinga Newsdesk
August 22, 2024 | 4:19 pm
Portfolio Pulse from Benzinga Newsdesk
August 09, 2024 | 11:08 am
Portfolio Pulse from Benzinga Newsdesk
August 01, 2024 | 12:03 pm
Portfolio Pulse from Benzinga Newsdesk
August 01, 2024 | 12:02 pm
Portfolio Pulse from Benzinga Newsdesk
June 27, 2024 | 11:07 am
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.